Shiseido Company, Limited

The General Hospital Corporation

Eth Zurich

Kentaro Kajiya

Michael Detmar

Shinichiro Haze

Yuzo Yoshida

Mio Nakamura

Masahiro Ota

Yuuko Matsumoto

The purpose of the present invention is to provide a substance related to the stabilization of capillary blood vessels. This invention is based on the discovery that an extract from a plant selected from the group consisting of, Siberian ginseng, andincreases gene expression of VE-cadherin or integrin &#x3b1;5.

VE-cadherin expression promoting agent and/or integrin &#x3b1;5 expression promoting agent

The purpose of this invention is to find a novel fragrance component effective for prevention or control of swelling, lymphedema, skin aging or obesity from the viewpoint of activation of lymph vessel function by promotion of the expression of VEGFC. This invention provides a swelling improving agent, lymph vessel activator and VEGFC production promoter characterized by containing one or a plurality of components selected from the group consisting of rose oxide, citronellyl acetate and niaouli oil.

VEGFC production promoter

The present invention relates to a method of evaluating cellulite using fibulin-3 and/or sarcoglycan gamma as an indicator in a harvested skin sample, and a method of evaluating a drug for improving, preventing or treating cellulite using fibulin-3 and/or sarcoglycan gamma as an indicator in cultured cells.

Method of evaluating cellulite and method of evaluating cellulite-effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator

This application features methods of inhibiting ultraviolet B-induced skin damage in a subject. The methods include administering a VEGF-C agonist to the subject.

Use of VEGF-C agonists for inhibiting ultraviolet B-induced skin damage

Provided are methods and compositions for the modulation of hepatocyte growth factor activity to regulate lymphatic vessel development and function. Methods and composition for the monitoring and treatment of skin disorders, lymphedema, and metastatic cancers are disclosed. Also described are methods of identifying inhibitors of hepatocyte growth factor dependent lymphangiogenesis.

Monitoring and modulating HGF/HGFR activity

Provided is a lymphatic vessel stabilizer composed of Tie2 activator. The Tie2 activator is preferably at least one type selected from the group consisting of angiopoietin 1 (Ang-1), extract ofspecies plants, extract of Siberian Ginseng and syringaresinol.

Lymphatic vessel stabilizer

This application features methods of treating (e.g., reducing, ameliorating, or preventing) skin damage (e.g., induced by UVB) by decreasing the level or activity of VEGF-A, e.g., in the skin, of a subject.

Growing community of inventors

Yokohama, Japan

Kentaro Kajiya